Incidence and prognostic impact of secondary cytogenetic aberrations in a series of 145 patients with mantle cell lymphoma.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Espinet Blanca, Salaverria Itziar, Beà Sílvia, Ruiz-Xivillé Neus, Balagué Olga, Salido Marta, Costa Dolors, Carreras Joaquim, Rodríguez-Vicente Ana Eugenia, Luís García Juan, Hernández-Rivas Jesús María, Calasanz María José, Siebert Reiner, Ferrer Ana, Salar Antonio, Carrió Ana, Polo Natividad, García-Marco José Antonio, Domingo Alicia, González-Barca Eva, Romagosa Vicenç, Marugán Isabel, López-Guillermo Armando, Millá Fuensanta, Luís Mate José, Luño Elisa, Sanzo Carmen, Collado Rosa, Oliver Isabel, Monzó Sebastià, Palacín Antonio, González Teresa, Sant Francesc, Salinas Ramon, Ardanaz María Teresa, Font Llorenç, Escoda Lourdes, Florensa Lourdes, Serrano Sergi, Campo Elias, Solé Francesc
Аннотация
Mantle cell lymphoma (MCL) is a mature B-cell neoplasm with an aggressive behavior, characterized by the t(11;14)(q13;q32). Several secondary genetic abnormalities with a potential role in the oncogenic process have been described. Studies of large MCL series using conventional cytogenetics, and correlating with proliferation and survival, are scarce. We selected 145 MCL cases at diagnosis, displaying an aberrant karyotype, from centers belonging to the Spanish Cooperative Group for Hematological Cytogenetics. Histological subtype, proliferative index and survival data were ascertained. Combined cytogenetic and molecular analyses detected CCND1 translocations in all cases, mostly t(11;14)(q13;q32). Secondary aberrations were present in 58% of patients, the most frequent being deletions of 1p, 13q and 17p, 10p alterations and 3q gains. The most recurrent breakpoints were identified at 1p31-32, 1p21-22, 17p13, and 1p36. Aggressive blastoid/pleomorphic variants displayed a higher karyotypic complexity, a higher frequency of 1p and 17p deletions and 10p alterations, a higher proliferation index and poor survival. Gains of 3q and 13q and 17p13 losses were associated with reduced survival times. Interestingly, gains of 3q and 17p losses added prognostic significance to the morphology in a multivariate analysis. Our findings confirm previous observations indicating that proliferation index, morphology and several secondary genetic alterations (3q gains and 13q and 17p losses) have prognostic value in patients with MCL. Additionally, we observed that 3q gains and 17p losses detected by conventional cytogenetics are proliferation-independent prognostic markers indicating poor outcome.